Cost-effectiveness of cabozantinib versus placebo for advanced neuroendocrine tumors from crossover-adjusted analysis in the United States and China

W Wenwang Lang B Bei Huang G Gaofeng Zhang L Lian Deng H Huirong Lu M Meijun Lu Y Yufei Pan (National Center for Liver Cancer)

Article Details

Volume / Issue Vol. 16, Issue 1
Published February 16, 2026
ISSN 2045-2322
Publisher Nature Portfolio

Journal Info

Scientific Reports

Nature Portfolio

ISSN: 2045-2322 Open Access Life Sciences

Authors (7)

W

Wenwang Lang

B

Bei Huang

G

Gaofeng Zhang

L

Lian Deng

H

Huirong Lu

M

Meijun Lu

Y

Yufei Pan

National Center for Liver Cancer